To better understand the effect of STM2457 in tumour microenvironment when combined with anti‐PD‐1 treatment, we conducted scRNA‐seq on tumour tissues treated with either anti‐PD‐1 alone or the combination of STM2457 and anti‐PD‐1 utilising the 10× Genomics platform (Figure 4A). The gene discussed is PDCD1; the disease is neoplasm.